{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-005127","form_type":"8-K","ticker":"MNPR","cik":"0001645469","company_name":"Monopar Therapeutics","filed_at":"2024-02-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.961467+00:00","generated_at":"2026-06-05T19:32:20.691099+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Monopar announces promising preclinical data for MNPR-101 radiopharma; Phase 1 trial in Australia cleared","bullets":["MNPR-101 targets uPAR, expressed in majority of triple-negative breast, colorectal, and pancreatic cancers.","Optimized MNPR-101-Zr imaging agent shows increased tumor uptake and reduced healthy tissue uptake in PET studies.","Single injection of MNPR-101 conjugated to Ac-225 or other therapeutic isotope led to near complete tumor elimination in mouse models.","Received HREC clearance in Australia to start Phase 1 dosimetry trial of MNPR-101-Zr in advanced cancer patients.","Company plans to present results at an upcoming scientific meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-005127","json":"https://secwatch.observer/filing/0001437749-24-005127.json","markdown":"https://secwatch.observer/filing/0001437749-24-005127.md","text":"https://secwatch.observer/filing/0001437749-24-005127.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924005127/0001437749-24-005127-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924005127/mnpr20240221_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T19:32:20.691099+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}